KRAS and neuroleptic malignant syndrome: Transcriptional profiling of genetically engineered, KRAS-induced mouse rhabdomyosarcomas (RMS) and non-myogenic sarcomas (NMS) identified 141 sarcoma-relevant genes; their function was evaluated using a customized shRBA screen.